Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | v-rel avian reticuloendotheliosis viral oncogene homolog A | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | nuclear factor of activated T cells 5 | 0.0178 | 0.1197 | 0.1197 |
Onchocerca volvulus | 0.0104 | 0 | 0.5 | |
Loa Loa (eye worm) | dihydrofolate reductase | 0.0717 | 1 | 1 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.0717 | 1 | 1 |
Echinococcus granulosus | dihydrofolate reductase | 0.0717 | 1 | 1 |
Schistosoma mansoni | dihydrofolate reductase | 0.0717 | 1 | 1 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.0717 | 1 | 1 |
Brugia malayi | Dihydrofolate reductase | 0.0717 | 1 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.0717 | 1 | 0.5 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0405 | 0.4904 | 0.5 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.0717 | 1 | 1 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0405 | 0.4904 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0405 | 0.4904 | 0.5 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0405 | 0.4904 | 0.5 |
Echinococcus granulosus | nuclear factor of activated T cells 5 | 0.0178 | 0.1197 | 0.1197 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0405 | 0.4904 | 0.5 |
Echinococcus multilocularis | dihydrofolate reductase | 0.0717 | 1 | 1 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0405 | 0.4904 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 20 uM | Induction of human IkappaBalpha stabilization in OCI-Ly3 cells by green light emiting IkappaBalpha-fused luciferase reporter gene assay | ChEMBL. | 18024113 |
EC50 (binding) | = 20 uM | Induction of human IkappaBalpha stabilization in OCI-Ly3 cells assessed as ratio of green light emiting IkappaBalpha-fused luciferase expression to red light emiting native luciferase expression | ChEMBL. | 18024113 |
EC50 (binding) | = 20 uM | Induction of human IkappaBalpha stabilization in OCI-Ly3 cells by green light emiting IkappaBalpha-fused luciferase reporter gene assay | ChEMBL. | 18024113 |
EC50 (binding) | = 20 uM | Induction of human IkappaBalpha stabilization in OCI-Ly3 cells assessed as ratio of green light emiting IkappaBalpha-fused luciferase expression to red light emiting native luciferase expression | ChEMBL. | 18024113 |
Efficacy (binding) | > 90 % | Inhibition of TNFalpha-stimulated human NFkappaB p65 RelA subunit nuclear translocation in HUVEC relative to control | ChEMBL. | 18024113 |
Efficacy (binding) | > 90 % | Inhibition of TNFalpha-stimulated human NFkappaB p65 RelA subunit nuclear translocation in HUVEC relative to control | ChEMBL. | 18024113 |
Efficacy (binding) | = 150 % | Induction of human IkappaBalpha stabilization in OCI-Ly3 cells by green light emiting IkappaBalpha-fused luciferase reporter gene assay relative to control | ChEMBL. | 18024113 |
Efficacy (binding) | = 150 % | Induction of human IkappaBalpha stabilization in OCI-Ly3 cells by green light emiting IkappaBalpha-fused luciferase reporter gene assay relative to control | ChEMBL. | 18024113 |
IC50 (binding) | > 10 uM | Inhibition of TNFalpha-stimulated human NFkappaB p65 RelA subunit nuclear translocation in HUVEC | ChEMBL. | 18024113 |
IC50 (binding) | > 10 uM | Inhibition of TNFalpha-stimulated human NFkappaB p65 RelA subunit nuclear translocation in HUVEC | ChEMBL. | 18024113 |
IC50 (binding) | > 57 uM | Inhibition of TNFalpha stimulated human NFkappaB-mediated beta lactamase gene expression in HUVEC | ChEMBL. | 18024113 |
IC50 (functional) | > 57 uM | Cytotoxicity against NFkappaB overexpressing human OCI-Ly3 cells after 4 hrs | ChEMBL. | 18024113 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.